New opportunities to treat bowel cancer

Research in mice identifies new treatment options for one of the most common cancers

New opportunities to treat bowel cancer

stemcellsprocess.jpgdoi: 10.1016/j.stemcr.2013.06.002
The schematic diagram of designer proteins and their binding sites at the Oct4 distal enhancer

Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.

More than one million people develop bowel cancer each year, which is one of the most common causes of death in cancer patients. One in ten colon cancers are caused by mutations in the BRAF gene, a gene commonly associated with skin cancers. Although successful treatments against BRAF mutations in skin cancers have been developed, these treatments have not been effective against BRAF mutations in colon cancer.

"Our approach encapsulates the aim of cancer genomics: to discover changes to DNA responsible for cancer development and pinpoint the 'Achilles heels' of cancer in order to identify new treatments. Our studies in mice revealed how genes co-operate to cause a specific subset of colon cancers. We identified main players, the order in which they occur during tumour progression, and the molecular processes how they turn relatively benign cell growth into threatening cancers. Such processes are targets for new treatments."

Professor Roland Rad, lead author from the Technical University of Munich and the German Cancer Research Center

The team looked at the development of BRAF-associated bowel cancer in mice, replacing the normal gene with a version containing a mutation identical with that in human cancers. Mice with the mutated BRAF gene developed hyperplastic polyps - abnormal growth of cell bundles in their intestine wall. These polyps progressed from benign growths to malignant cancers.

In the mutant mice, the team uncovered a stepwise process of genetic alterations, which drive the development of this type of colon cancer. Some alterations activate genes such as BRAF, making them potentially cancerous. Others disrupt protective proteins such as p53, inactivating their ability to suppress cancer progression.

"Understanding the genetic makeup of different colorectal cancer subtypes will guide therapeutic decision making in the future. Our ability to engineer specific genetic alterations in mice allows us to study the function of cancer genes and to model specific cancer subtypes at an organismal level. Such mouse models are also invaluable for testing anticancer drugs before using them in clinical trials."

Professor Allan Bradley, senior author from the Wellcome Trust Sanger Institute

The team tested a wide range of existing and candidate drugs for their ability to slow down or prevent growth of mouse colon cancer and human colon cancer cells, finding several highly effective approaches. These were tested individually or in combination with one another to find the most powerful therapies.

Mice with the BRAF-associated colon cancer had very similar therapeutic responses to those of BRAF-associated cancer cells from patients with colon cancer, highlighting the effectiveness of mice in preclinical cancer research.

The team found multiple drugs and drug combinations that were effective against human colon cancer cells. These are promising results for alternative second- or third-line treatments after resistance to the first round of treatment against this occurs.

"Our results illustrate the power of combining genomic information with large-scale drug screening to provide new targeted treatment strategies for patients with specific cancer subtypes."

Dr Ultan McDermott, author from the Wellcome Trust Sanger Institute

    Notes to Editors
    Publications
    • A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.

      Rad R, Cadiñanos J, Rad L, Varela I, Strong A et al.

      Cancer cell 2013;24;1;15-29

    Funding

    The work was supported by the Wellcome Trust and the Helmholtz Gemeinschaft, Deutsche Forschungsgemeinschaft, FEBS, and International Human Frontiers Science Program Organization.

    Participating Centres
    • Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, 81675, München, Germany
    • German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
    • Wellcome Trust Sanger Institute, Genome Campus, Hinxton/Cambridge CB10 1SA, UK
    • Instituto de Medicina Oncológica y Molecular de Asturias (IMOMA), 33193 Oviedo, Spain
    • Instituto de Biomedicina y Biotecnología de Cantabria, 39011 Santander, Spain
    • Department of Pathology, Ludwig-Maximilians-Universität, 80337 München, Germany
    • Department of Veterinary Medicine, University of Cambridge, CB3 0ES Cambridge, UK
    • Instituto Universitario de Oncología, Universidad de Oviedo, 33006 Oviedo, Spain
    • Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, 28049 Madrid, Spain
    • School of Pathology and Laboratory Medicine, University of Western Australia, WA 6009, Australia
    Selected Websites
    Contact the Press Office

    Dr Samantha Wynne, Media Officer

    Tel +44 (0)1223 492 368

    Emily Mobley, Media Officer

    Tel +44 (0)1223 496 851

    Wellcome Trust Sanger Institute,
    Hinxton,
    Cambridgeshire,
    CB10 1SA,
    UK

    Mobile +44 (0) 7900 607793

    Recent News

    Genome editing reveals role of gene important for human embryo development

    CRISPR-Cas9 genome editing shows that the protein OCT4 is essential in very early days of human embryo development

    Huge genetic diversity among Papuan New Guinean peoples revealed

    Genetic diversity found to mirror linguistic and cultural diversity among Papuan New Guinean people

    Immunotherapy treatment option for selected breast cancer patients, genetic study suggests

    Opens up the possibility of another therapy option for approximately 1,000 breast cancer patients in the UK